Clinical study on the sedation and analgesia effect of dexmedetomidine combined with sufentanil in severe acute pancreatitis patients with mechanical ventilation

Abstract

Objective To investigate the sedation and analgesia clinical effects of dexmedetomidine and midazolam sufentanil in severe acute pancreatitis patients with mechanical ventilation. Methods Sixty four patients with mechanical ventilation in severe acute pancreatitis were randomly divided into dexmedetomidine and midazolam groups, and 32 cases in each group. All patients were routinely given sufentanil continuous intravenous analgesia. The patients in dexmedetomidine group received dexmedetomidine 1.0 μg/kg loading dose by intravenous injection and followed with 0.2~0.7 μg/(kg·h) continuous intravenous infusion. The patients in midazolam group received midazolam: 0.05 mg/kg loading dose by intravenous injection and followed with 0.02~0.08 mg/(kg·h) continuous intravenous infusion. The sedation and analgesia effects and inflammation index changes in two groups were observed. Results The analgesia and sedation onset time, awake time and time of live in intensive care unit(ICU) in dexmedetomidine group were significantly superior to the midazolam group (P<0.05). Before weaning from mechanical ventilation the white blood cell count, C-reaction protein (CRP), heart rate, and respiratory frequency index in dexmedetomidine group were significantly better than those in midazolam group (P<0.05). The adverse event's incidence rate in dexmedetomidine group (9.38%) was ignificantly lower s than that in midazolam group (31.25%) (P<0.05). Conclusions The application of dexmedetomidine combined with sufentanil in severe acute pancreatitis patients with mechanical ventilation may play a good role of sedative and analgesic effects, and alleviating the inflammatory reaction of patients, as well as fewer adverse events. Key words: Dexmedetomidine/AD; Sufentanil/AD; Pancreatitis/SU; Analgesia; Conscious sedation; Respiration, artificial